Sanofi (SAN) Aktievy
Sanofi är ett hälsovårdsföretag som bedriver forskning, utveckling, tillverkning och marknadsföring av terapeutiska lösningar i USA, Europa och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 4/6 |
Belöningar
Riskanalys
SAN Community Fair Values
Create NarrativeSee what 246 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sanofi Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €77.79 |
| 52 veckors högsta | €91.15 |
| 52 veckors lägsta | €71.25 |
| Beta | 0.28 |
| 1 månads förändring | 1.36% |
| 3 månaders förändring | 1.18% |
| 1 års förändring | -11.07% |
| 3 års förändring | -20.73% |
| 5 års förändring | -12.05% |
| Förändring sedan börsintroduktionen | 87.00% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 20
SAN: Future Upside Will Hinge On Pipeline Execution And Margin Resilience
Sanofi's updated analyst price target has edged lower to about €94 from roughly €97, with analysts pointing to slightly softer revenue growth assumptions, a marginally higher discount rate and a lower future P/E multiple, partly offset by a modestly higher profit margin outlook. Analyst Commentary Recent commentary on Sanofi sits against a backdrop of higher target prices across parts of the European market, with several banks seeing room for upside in other large cap stocks.
Uppdatering av berättelse • Aug 05
SAN: Vaccine Approvals And Pipeline Decisions Will Support Future Upside
Analysts have raised their fair value estimate for Sanofi from €107.20 to €112.00. This change reflects updated views that include slightly lower revenue growth assumptions, a modestly higher profit margin profile, and a small adjustment to the future P/E multiple.Recent updates
Uppdatering av berättelse • Aug 20
SAN: Future Upside Will Hinge On Pipeline Execution And Margin Resilience
Sanofi's updated analyst price target has edged lower to about €94 from roughly €97, with analysts pointing to slightly softer revenue growth assumptions, a marginally higher discount rate and a lower future P/E multiple, partly offset by a modestly higher profit margin outlook. Analyst Commentary Recent commentary on Sanofi sits against a backdrop of higher target prices across parts of the European market, with several banks seeing room for upside in other large cap stocks.Uppdatering av berättelse • Aug 05
SAN: Vaccine Approvals And Pipeline Decisions Will Support Future Upside
Analysts have raised their fair value estimate for Sanofi from €107.20 to €112.00. This change reflects updated views that include slightly lower revenue growth assumptions, a modestly higher profit margin profile, and a small adjustment to the future P/E multiple.Uppdatering av berättelse • Jul 22
SAN: New Drug Approvals And AI Discovery Partnership Will Support Future Upside
Sanofi's updated analyst price target has shifted from €112.00 to €107.20, reflecting revised assumptions around discount rates, revenue growth, profit margins and future P/E. Analysts view these changes as better aligning the stock's valuation with current fundamentals.
Uppdatering av berättelse • Jul 02
SAN: Pipeline Approvals And R&D Execution Will Shape Future Share Support
Analysts have lifted the indicative fair value for Sanofi to €82.00 from €72.40, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with recent upward revisions to price targets seen across parts of the European market. Analyst Commentary Analysts covering Sanofi have framed the updated fair value in the context of broader reassessments across European equities, with the new €82.00 level positioned as an attempt to reflect current assumptions on growth, profitability and P/E multiples rather than a shift driven by any single catalyst.Uppdatering av berättelse • Jun 18
SAN: Future Upside Will Hinge On AI Execution Across R&D Workflows
Sanofi's analyst price target has been revised slightly to €96.70 from €97.10. This change reflects updated views on its revenue growth outlook, profit margin assumptions and a modestly adjusted future P/E multiple, according to recent analyst commentary.Uppdatering av berättelse • Jun 04
SAN: Future Upside Will Depend On AI Execution And R&D Pipeline Delivery
Analysts have nudged their fair value estimate for Sanofi higher from €95.53 to €97.10, citing slightly adjusted assumptions on discount rate, revenue growth, profit margins and future P/E as the basis for the updated price target. Analyst Commentary Bullish analysts framing the updated fair value for Sanofi around €97.10 are effectively signaling confidence that the company can execute in line with, or slightly ahead of, their refined assumptions on discount rate, revenue trajectory, margins and implied future P/E.Analysartikel • May 04
Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings
Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...Uppdatering av berättelse • Apr 22
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution
Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.Ny berättelse • Apr 14
Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade
Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 07
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion
Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.Ny berättelse • Mar 31
Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability
Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Mar 24
SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength
Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.Uppdatering av berättelse • Mar 09
SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience
Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.Uppdatering av berättelse • Feb 23
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability
Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.Uppdatering av berättelse • Feb 09
SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience
Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.Uppdatering av berättelse • Jan 25
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.Uppdatering av berättelse • Jan 11
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.Uppdatering av berättelse • Dec 25
SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline
Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.Uppdatering av berättelse • Dec 11
SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline
Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.Uppdatering av berättelse • Nov 27
SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals
Sanofi's analyst price target has been modestly adjusted downward from $106.85 to $106.26. Analysts point to slight improvements in profit margin and future valuation metrics while maintaining a broadly stable outlook.Uppdatering av berättelse • Nov 10
SAN: Forward Momentum Will Rely On Pipeline Success And Operational Execution
Sanofi's analyst price target saw a slight decrease to $106.85 from $106.90. Analysts cite moderating revenue growth expectations and a slightly higher discount rate impacting the updated valuation.Aktieägarnas avkastning
| SAN | FR Pharmaceuticals | FR Marknad | |
|---|---|---|---|
| 7D | 1.8% | 4.2% | -1.8% |
| 1Y | -11.1% | -5.3% | 2.0% |
Avkastning vs industri: SAN presterade sämre än French Pharmaceuticals branschen som gav -5.3 % under det senaste året.
Avkastning vs Marknaden: SAN presterade sämre än French marknaden som gav 2 % under det senaste året.
Prisvolatilitet
| SAN volatility | |
|---|---|
| SAN Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stabil aktiekurs: SAN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för French.
Volatilitet över tid: SAN s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1994 | 74,846 | Belen Garijo Lopez | www.sanofi.com |
Sanofi är ett hälsovårdsföretag som bedriver forskning, utveckling, tillverkning och marknadsföring av terapeutiska lösningar i USA, Europa och internationellt. Företaget tillhandahåller immunologi och inflammation, sällsynta sjukdomar, neurologi, onkologi samt andra läkemedel och vacciner. Företaget erbjuder också pediatriska vacciner mot poliomyelit, kikhosta och haemophilus influenzae typ b (Hib), skydd mot respiratoriskt syncytialvirus och hexavalenta kombinationsvacciner som skyddar mot difteri, stelkramp, kikhosta, polio, Hib och hepatit B, influensavacciner, boostervacciner, meningitvacciner samt resevacciner och endemiska vacciner, däribland hepatit A-, tyfoid-, gula febern- och rabiesvacciner.
Sanofi Sammanfattning av grunderna
| SAN grundläggande statistik | |
|---|---|
| Börsvärde | €93.20b |
| Vinst(TTM) | €3.94b |
| Intäkter(TTM) | €48.92b |
23.7x
P/E-förhållande1.9x
P/S-förhållandeÄr SAN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SAN resultaträkning (TTM) | |
|---|---|
| Intäkter | €48.92b |
| Kostnad för intäkter | €12.99b |
| Bruttovinst | €35.93b |
| Övriga kostnader | €31.99b |
| Intäkter | €3.94b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Oct 30, 2026
| Vinst per aktie (EPS) | 3.29 |
| Bruttomarginal | 73.45% |
| Nettovinstmarginal | 8.05% |
| Skuld/egenkapitalförhållande | 31.2% |
Hur har SAN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
5.3%
Aktuell utdelningsavkastning126%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/20 02:31 |
| Aktiekurs vid dagens slut | 2026/08/20 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Sanofi bevakas av 51 analytiker. 21 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| null null | Banco de Sabadell. S.A. |